⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716245 | 0.70 | — | — | |
| SCHEMBL285898 | 0.68 | — | — | |
| SCHEMBL60658 | 0.53 | — | — | |
| SCHEMBL21017223 | 0.53 | — | — | |
| SCHEMBL1470777 | 0.53 | — | — | |
| SCHEMBL24637544 | 0.53 | — | — | |
| SCHEMBL10408 | 0.50 | — | — | |
| SCHEMBL24425438 | 0.48 | — | — | |
| SCHEMBL24425442 | 0.48 | — | — | |
| SCHEMBL24211018 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | claimed |
| WO-2024092185-A1 | ACYL SULFONAMIDE COMPOUNDS AS INHIBITORS OF POLYOMAVIRUS | VIA NOVA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | claimed |
| US-20240124489-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-18 | — | — | US | claimed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | claimed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | claimed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| WO-2024010782-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | claimed |
| US-11655243-B2 | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2023-05-23 | — | — | US | claimed |
| US-20220289739-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-15 | — | — | US | claimed |
| CN-114126713-A | Substituted benzimidazolone compounds | 百时美施贵宝公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2021067326-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-08 | — | — | WO | claimed |
| WO-2020227484-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-12 | — | — | WO | claimed |
| EP-3724197-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-10-21 | — | — | EP | claimed |
| EP-3704113-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | claimed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | claimed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | claimed |
| WO-2020002270-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-01-02 | — | — | WO | claimed |
| WO-2019116256-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | claimed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | claimed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | claimed |